Alpa Laboratories Limited (ALPA.BO)
INR 105.3
(1.4%)
INR 105.3
(1.4%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 184.49 Million INR | -8.83% |
| 2022 | 67.47 Million INR | -15.27% |
| 2021 | 79.63 Million INR | 15.42% |
| 2020 | 68.99 Million INR | 267.04% |
| 2019 | 18.79 Million INR | 163.3% |
| 2018 | -29.69 Million INR | -1214.71% |
| 2017 | 2.66 Million INR | -93.06% |
| 2016 | 38.4 Million INR | -23.55% |
| 2015 | 50.23 Million INR | 572.72% |
| 2014 | 7.46 Million INR | 126.12% |
| 2013 | -28.58 Million INR | -80.17% |
| 2012 | -15.86 Million INR | -201.26% |
| 2011 | 15.67 Million INR | 4740.74% |
| 2010 | -337.66 Thousand INR | -101.82% |
| 2009 | 18.5 Million INR | 47.89% |
| 2008 | 12.51 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -122 Thousand INR | -100.41% |
| 2023 Q4 | 29.82 Million INR | -43.76% |
| 2023 Q1 | -14.17 Million INR | -116.33% |
| 2023 Q2 | 28.6 Million INR | 301.76% |
| 2023 Q3 | 53.02 Million INR | 85.41% |
| 2023 FY | 61.51 Million INR | -8.83% |
| 2022 Q2 | -60.5 Million INR | -639.15% |
| 2022 FY | 67.47 Million INR | -15.27% |
| 2022 Q4 | 86.8 Million INR | 244.14% |
| 2022 Q3 | 25.22 Million INR | 141.69% |
| 2022 Q1 | 11.22 Million INR | 183.17% |
| 2021 Q3 | 32.9 Million INR | 5.85% |
| 2021 Q4 | 3.96 Million INR | -87.96% |
| 2021 Q2 | 31.08 Million INR | 39.22% |
| 2021 Q1 | 22.32 Million INR | 158.34% |
| 2021 FY | 79.63 Million INR | 15.42% |
| 2020 Q2 | 4.31 Million INR | -86.66% |
| 2020 Q4 | 8.64 Million INR | -76.94% |
| 2020 Q1 | 32.34 Million INR | 341.6% |
| 2020 FY | 68.99 Million INR | 267.04% |
| 2020 Q3 | 37.47 Million INR | 768.75% |
| 2019 Q3 | 26.07 Million INR | 504.5% |
| 2019 FY | 18.79 Million INR | 163.3% |
| 2019 Q1 | 13.02 Million INR | 183.46% |
| 2019 Q2 | 4.31 Million INR | -66.87% |
| 2019 Q4 | -13.38 Million INR | -151.33% |
| 2018 Q3 | 25.37 Million INR | 510.49% |
| 2018 Q1 | -1.48 Million INR | 0.0% |
| 2018 FY | -29.69 Million INR | -1214.71% |
| 2018 Q4 | -15.6 Million INR | -161.49% |
| 2018 Q2 | 4.15 Million INR | 379.21% |
| 2017 FY | 2.66 Million INR | -93.06% |
| 2016 FY | 38.4 Million INR | -23.55% |
| 2015 FY | 50.23 Million INR | 572.72% |
| 2015 Q2 | 61.64 Million INR | 96.48% |
| 2015 Q1 | 31.37 Million INR | 269.59% |
| 2014 Q1 | -16.35 Million INR | -49.96% |
| 2014 Q2 | -7.13 Million INR | 56.38% |
| 2014 Q3 | 29.88 Million INR | 518.9% |
| 2014 Q4 | -18.5 Million INR | -161.91% |
| 2014 FY | 7.46 Million INR | 126.12% |
| 2013 FY | -28.58 Million INR | -80.17% |
| 2013 Q2 | -21.44 Million INR | -179.91% |
| 2013 Q3 | 6.18 Million INR | 128.83% |
| 2013 Q4 | -10.9 Million INR | -276.46% |
| 2013 Q1 | -7.66 Million INR | 41.87% |
| 2012 Q3 | -11.45 Million INR | -1131.14% |
| 2012 Q2 | 1.11 Million INR | -85.13% |
| 2012 Q1 | 7.47 Million INR | 1848.49% |
| 2012 FY | -15.86 Million INR | -201.26% |
| 2012 Q4 | -13.17 Million INR | -15.02% |
| 2011 Q3 | 6.56 Million INR | 0.0% |
| 2011 Q4 | -427.28 Thousand INR | -106.51% |
| 2011 FY | 15.67 Million INR | 4740.74% |
| 2010 FY | -337.66 Thousand INR | -101.82% |
| 2009 FY | 18.5 Million INR | 47.89% |
| 2008 FY | 12.51 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 96.796% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 99.563% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 97.945% |
| Granules India Limited | 6.81 Billion INR | 97.293% |
| Indoco Remedies Limited | 1.29 Billion INR | 85.726% |
| Achyut Healthcare Limited | 4.43 Million INR | -4057.21% |
| Ajanta Pharma Limited | 19.67 Billion INR | 99.062% |
| Alkem Laboratories Limited | 19.46 Billion INR | 99.052% |
| Brooks Laboratories Limited | 14.44 Million INR | -1177.68% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 89.258% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 85.012% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 99.728% |
| Eris Lifesciences Limited | 5.18 Billion INR | 96.439% |
| FDC Limited | 2.98 Billion INR | 93.822% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 97.163% |
| Gufic Biosciences Limited | 1.32 Billion INR | 86.127% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 95.826% |
| Ipca Laboratories Limited | 7.98 Billion INR | 97.688% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | 63.691% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 221.414% |
| Lasa Supergenerics Limited | -458 Million INR | 140.283% |
| Laurus Labs Limited | 3.94 Billion INR | 95.328% |
| Lupin Limited | 28.04 Billion INR | 99.342% |
| Mankind Pharma Limited | 21.51 Billion INR | 99.143% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -83.945% |
| Megasoft Limited | -121.1 Million INR | 252.346% |
| NATCO Pharma Limited | 25.96 Billion INR | 99.289% |
| Piramal Pharma Limited | 4.55 Billion INR | 95.951% |
| RPG Life Sciences Limited | 2.29 Billion INR | 91.951% |
| Sigachi Industries Limited | 1.47 Billion INR | 87.482% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 99.823% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 95.996% |
| Syncom Formulations (India) Limited | 249.25 Million INR | 25.979% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | 67.616% |
| Windlas Biotech Limited | 1.29 Billion INR | 85.796% |
| ZIM Laboratories Limited | 253.82 Million INR | 27.314% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 99.572% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 104.483% |
| Divi's Laboratories Limited | 33.08 Billion INR | 99.442% |
| Hester Biosciences Limited | 364.81 Million INR | 49.427% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 93.378% |
| Amrutanjan Health Care Limited | 457.54 Million INR | 59.677% |
| Bal Pharma Limited | 233.9 Million INR | 21.124% |
| Strides Pharma Science Limited | 5.22 Billion INR | 96.47% |
| Venus Remedies Limited | 534.65 Million INR | 65.492% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 94.102% |
| Nectar Lifesciences Limited | 923.8 Million INR | 80.029% |
| Shilpa Medicare Limited | 1.36 Billion INR | 86.496% |
| Aarti Drugs Limited | 7.14 Billion INR | 97.419% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 88.446% |
| Suven Life Sciences Limited | -1.22 Billion INR | 115.051% |
| Ind-Swift Limited | 1.22 Billion INR | 84.951% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 98.708% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 104.789% |
| Themis Medicare Limited | 392.58 Million INR | 53.005% |
| Hikal Limited | 32.11 Million INR | -474.578% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 99.272% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | 70.551% |
| Wockhardt Limited | -670 Million INR | 127.537% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 96.444% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -1934.437% |
| Neuland Laboratories Limited | 5.31 Billion INR | 96.531% |
| Morepen Laboratories Limited | 4.17 Billion INR | 95.58% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | 11.321% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -571.924% |